Donald Glass
Dermatology · Dallas, TXNPI 1508052036
Payments from drug & device makers
What this record shows
This record is dominated by grants: $330,000 of the $346,946 with a category attached, or 95.1%. Sanofi accounts for 95.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $330,071 and has fallen 99.9% since, to $181 in 2025. Among dermatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 11 payments — averaging $31,541 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$330K
- Pfizer$12K
- UCB, Inc.$3K
- AbbVie$2K
- Kyowa Kirin, Inc.$64
- Sun Pharmaceutical Industries Inc.$64
- plus $96 from 2 others
Across 1 payment — averaging $500,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$500K
What the payments were for
- Consulting fees$7,4502%
- Speaking & faculty fees$9,2003%
- Grants$330,00095%
- Food & beverage$2950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 2 | $330,071 |
| Pfizer | 3 | $11,700 |
| UCB, Inc. | 1 | $2,840 |
| AbbVie | 1 | $2,110 |
| Kyowa Kirin, Inc. | 1 | $64 |
| Sun Pharmaceutical Industries Inc. | 1 | $64 |
| Regeneron | 1 | $53 |
| Janssen Research & Development, LLC | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Humira$2,110
How this compares
$346,946 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 122 | $5,910 |
| Pentoxifylline | 48 | $1,935 |
| Desonide | 16 | $1,367 |
| Doxycycline Hyclate | 43 | $1,191 |
| Fluorouracil | 15 | $718 |
| Triamcinolone Acetonide | 43 | $700 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 13 | $440 |
| Ketoconazole | 32 | $371 |
| Mupirocin | 47 | $353 |
| Doxycycline Monohydrate | 12 | $249 |
| Terbinafine Hcl | 11 | $151 |
| ValacyclovirValacyclovir Hcl | 11 | $121 |
| Gabapentin | 13 | $104 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Dallas
- Jennifer CatherDallas$1.3M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
- So Yeon PaekDallas$812K
- Martin MenterDallas$512K
- Mary HornerDallas$448K
- William AbramovitsDallas$325K
- Mary FleischliDallas$153K
- Adean KingstonDallas$141K
- Edward LainAustin$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.